Skip to content
Quebec News Tribune – Lifestyle
Author:
Vivos Therapeutics, Inc
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
November 16, 2026
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
October 21, 2026
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
October 19, 2026
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
October 15, 2026
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
September 29, 2026
Vivos Therapeutics Reduces Debt, Boosts Equity for Nasdaq Compliance
September 8, 2026
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
August 29, 2026
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
August 14, 2026
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
August 14, 2026
Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations
August 11, 2026
1
2
Next Page
→